<DOC>
	<DOCNO>NCT02098291</DOCNO>
	<brief_summary>This study design determine effect jaundice ability G17DT generate antibody treatment biliary obstruction due advance pancreatic cancer .</brief_summary>
	<brief_title>An Open , Single-center Study Determine Antibody Repsonse Gastrimmune Its Safety Tolerability Patients With Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients histological cytological confirmation pancreatic carcinoma suitable pancreatic tumour resection curative intent Patients receive chemotherapy previous month would either receive chemotherapy period study would commence gemcitabine treatment week 4 study Male female patient 18 year age Patients life expectancy least 2 month Patients must give write informed consent Patients Karnofsky Performance Status score â‰¥ 50 % Patients would receive chemotherapy period Extension Survival Study , except concomitant gemcitabine ongoing visit ( extension study ) History malignant disease except nonmelanomatous skin carcinoma situ carcinoma uterine cervix Concomitant use anticipate use period study radiotherapy Chemotherapy previous month precede screening , anticipate concomitant use chemotherapy screen week 4 study anticipate useof chemotherapeutic agent gemcitabine week 4 period study Use past month concomitant use immunosuppressant , include systemic ( i.e . oral inject ) corticosteroid Females pregnant , plan become pregnant lactating Patients take part another study involve investigational license drug device three month precede enrolment study Haematological indicator : Haemoglobin &lt; 9.5g/dl White blood cell count &lt; 3.5 x 109/l Platelets &lt; 100 x 109/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>